Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
BJU International|February 12, 2017
Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trialShankar Siva, Daniel Pham, Tomas Kron, et al.
International Journal of Radiation Oncology, Biology, Physics|October 18, 2020
Safety, Efficacy, and Patterns of Failure After Single-Fraction Stereotactic Body Radiation Therapy (SBRT) for OligometastasesPaolo Sogono, Mathias Bressel, Steven David, et al.
International Journal of Radiation Oncology, Biology, Physics|October 25, 2011
Twenty-five-year experience with radical chemoradiation for anal cancerJonathan M Tomaszewski, Emma Link, Trevor Leong, et al.
ANZ Journal of Surgery|October 6, 2018
Treatment of patients with primary retroperitoneal sarcoma: predictors of outcome from an Australian specialist sarcoma centreHayden A Snow, Tatiana X Hitchen, Jessica Head, et al.
Radiation Oncology (London, England)|February 14, 2024
Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancerMuhammad Ali, Kendrick Koo, David Chang, et al.
BJU International|June 28, 2025
Impact of the R.E.N.A.L. complexity score on outcomes of stereotactic ablative body radiotherapy for primary renal cell carcinomaMuhammad Ali, Mathias Bressel, David Chang, et al.
European Urology|September 20, 2018
Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical TrialShankar Siva, Mathias Bressel, Declan G Murphy, et al.
European Urology Open Science|October 3, 2022
Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell CarcinomaCristian Udovicich, Jason Callahan, Mathias Bressel, et al.
International Journal of Radiation Oncology, Biology, Physics|June 25, 2022
Impact of Medical Operability and Total Metastatic Ablation on Outcomes After SABR for OligometastasesShankar Siva, Gavin Jones, Mathias Bressel, et al.
Asia-Pacific Journal of Clinical Oncology|November 4, 2025
Real-World Trends and Outcomes for Localized High-Grade Soft Tissue Sarcoma: Insights from a Sarcoma Unit in AustraliaAdel Shahnam, Jeremy Lewin, Anne Hamilton, et al.
Pageof 6